Cancer Clinical Trials Office Blog

News & Updates from the CCTO

CCTO Trial Activation Dashboard

-

CCTO is proud to announce the launch of CCTO Trial Activation Dashboard, a new tool within CCTO web page (http://med.stanford.edu/ccto.html -> Intake Request tab) that allows you to review your trial activation status all in one place. We’ve spent the last several months building this dashboard, integrating trial activation data points from CCTO Intake, SERA and OnCore.  Besides service milestone status for requested services, the dashboard will offer information on Specialist assignment, IRB, NOA, SRC, and more.  This dashboard is refreshed daily.

CCTO Activation Dashboard Link

We are already planning further enhancement to this tool.  Please send your feedback and suggestion to CCTO-Intake@stanford.edu.

Thank you,

CCTO Intake

Brentuximab Vedotin Receives FDA Approval for Peripheral T-Cell Lymphoma

-

Seattle Genetics announced FDA approval for Brentuximab Vedotin (Adcetris) in combination with chemotherapy for peripheral T-cell Lymphoma, based on the ECHELON-2 (SGN35-014) study conducted in part at Stanford by the Advani team members. For more information please see the press release.

Congratulations to Jessica, Sipra, Thu and the rest of the team for their contribution to the approval of treatment for this difficult to treat disease.

Larotrectinib Receives FDA Approval

-

The Developmental Therapeutics team is celebrating a new FDA approval based on data generated on the study LOXO-TRK-15002. More than 10% of the overall data leading to the approval of Larotrectinib (Vitrakvi) was generated by Dr. Kummar and her team at Stanford. Many thanks for their hard work on this clinical trial.

Larotrectinib is an oral agent for management of solid tumors with NTRK gene fusions, a rare oncogenic driver found in more than 25 types of cancers, from sarcomas to GI and lung cancers, from breast cancer to melanoma. It is a new alternative treatment for adults and pediatric patients with metastatic or progressive disease, including cases where tumor resection is likely to cause injury or disability. It is the first therapy approved for this type of genomic abnormality, regardless of cancer type. It is also only the second drug approved for a tissue agnostic indication (across tumor histologies).

For more information please see the FDA press release.

Staff Kudo

-

Congratulations to Thu Tran from the Lymphoma team, who was published as a co-author in an article recently published in the NEJM about Dr. Advani’s anti CD-47 study! This article was mentioned last week in the blog and can be read here. Great job, Thu!